Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Syros Pharmaceuticals Inc.

Latest From Avexa Ltd.

Muck and brass: Avexa mines rich seam of novel pharma funding

Faced with the need to secure additional funding to complete late-stage trials of its lead drug and for other pipeline projects in a difficult financing environment, the Australian company Avexa considered a wide range of both standard and non-traditional options.

Infectious Diseases Singapore

Deals Of The Week: AstraZeneca/Ardelyx, Roche/Inception, GlaxoSmithKline/Aeras

Vaxxas thinks its vaccine-enhancement technology platform, Nanopatch, can bring in milestones and royalties just like a biotech drug candidate by offering increased potency and easier administration to makers of vaccines.

BioPharmaceutical Europe

Adverse events with Gilead’s GS 9190 may increase HCV polymerase inhibitor scrutiny

Following the reports of two serious adverse events in two separate Phase IIb studies of GS 9190 in hepatitis C-infected patients, Gilead Sciences is amending the trial designs and discontinuing dosing of the drug candidate, following consultation with the US FDA.

Gastrointestinal Infectious Diseases

Avexa mulls options as it closes lead HIV programme for apricitabine

Australian biotech Avexa said it would explore strategic alternatives for the company after ceasing further development of its lead HIV programme for its NRTI apricitabine (ATC), following unsuccessful partnering discussions with global pharmaceutical companies. Shares in the company plummeted by 78% on the news to close at 3 Australian cents on 10 May.

Infectious Diseases Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Syros Pharmaceuticals Inc.
  • Senior Management
  • Nancy Simonian, MD, CEO
    Kyle Kuvalanka, COO
    Eric R Olson, PhD, CSO
    David A Roth, MD, CMO
  • Contact Info
  • Syros Pharmaceuticals Inc.
    Phone: (617) 744-1340
    620 Memorial Dr.
    Ste. 300
    Cambridge, MA 02139